Journal article
Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins
Current fungal infection reports, Vol.5(3), pp.120-127
09/2011
DOI: 10.1007/s12281-011-0053-y
Abstract
Antifungal susceptibility testing of Candida against the echinocandin antifungal agents (anidulafungin [ANF], caspofungin [CSF], micafungin [MCF]) has been standardized by the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antifungal Testing. The CLSI proposed a single set of clinical breakpoints (CBPs) for all three echinocandins and all species of Candida: susceptible, minimum inhibitory concentration (MIC) ≤ 2 μg/mL; nonsusceptible, MIC > 2 μg/mL. Subsequently, these CBPs have been shown to lack sensitivity in detecting strains of Candida with acquired resistance mechanisms associated with treatment failure. Studies using the CLSI method have defined wild-type (WT) MIC distributions and epidemiologic cutoff values (ECVs) for each echinocandin and the common species of Candida. The ECVs serve as a sensitive means of discriminating WT strains from those with acquired resistance mechanisms. WT MIC distributions revealed ECV ranges of 0.03 to 0.25 μg/mL for all major species except C. parapsilosis (1–4 μg/mL) and C. guilliermondii (4–16 μg/mL). These ECVs reliably differentiate WT strains of each species from non-WT strains containing fks mutations. These data, coupled with additional biochemical, clinical, pharmacokinetic, and pharmacodynamic considerations, have resulted in new CBPs of ≤0.25 μg/mL (susceptible), 0.5 μg/mL (intermediate), and ≥1 μg/mL (resistant) for ANF, CSF, and MCF for C. albicans, C. tropicalis, and C. krusei. For these agents and C. parapsilosis, the new CBPs are ≤2 μg/mL (susceptible), 4 μg/mL (intermediate), and ≥8 μg/mL (resistant). For C. glabrata, the CBPs for ANF and CSF are ≤0.12 μg/mL (susceptible), 0.25 μg/mL (intermediate), and ≥0.5 μg/mL (resistant), whereas those for MCF are ≤0.06 μg/mL, 0.12 μg/mL, and ≥0.25 μg/mL, respectively. Application of both ECVs and the lower species-specific CBPs for the echinocandins has proven useful in both resistance surveillance and clinical care and will serve as an important step in international harmonization of in vitro susceptibility testing of this important antifungal class.
Details
- Title: Subtitle
- Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins
- Creators
- Michael Pfaller - University of Iowa College of Medicine Iowa City IA 52242 USADaniel Diekema - University of Iowa College of Medicine Iowa City IA 52242 USAMariana Castanheira - JMI Laboratories North Liberty IA 52317 USARonald Jones - JMI Laboratories North Liberty IA 52317 USA
- Resource Type
- Journal article
- Publication Details
- Current fungal infection reports, Vol.5(3), pp.120-127
- Publisher
- Current Science Inc; New York
- DOI
- 10.1007/s12281-011-0053-y
- ISSN
- 1936-3761
- eISSN
- 1936-377X
- Language
- English
- Date published
- 09/2011
- Academic Unit
- Infectious Diseases; Pathology; Internal Medicine; Epidemiology
- Record Identifier
- 9984001172102771
Metrics
14 Record Views